FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Wendy C. Weinberg et al.|Clinical Cancer Research|2014Cited by 350
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E MutationGeoffrey Kim, Richard Pazdur, Amy E. McKee et al.|Clinical Cancer Research|2014Cited by 215
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryKatherine A. Thornton, Richard Pazdur, Geoffrey Kim et al.|Clinical Cancer Research|2012Cited by 149